Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes

•The maximum tolerated dose of liothyronine (L-T3) was 75 mcg (n = 15).•The most common adverse events reported with L-T3 were poor sleep and loose stools.•No serious adverse events were reported with L-T3 over one week.•Visual evoked potentials showed good reliability over one week.•Sloan low contr...

Full description

Saved in:

Bibliographic Details
Published in:	Multiple sclerosis and related disorders 2020-06, Vol.41, p.102015-102015, Article 102015
Main Authors:	Wooliscroft, Lindsey, Altowaijri, Ghadah, Hildebrand, Andrea, Samuels, Mary, Oken, Barry, Bourdette, Dennis, Cameron, Michelle
Format:	Article
Language:	English
Subjects:	Adult Clinical trial Evoked potentials Evoked Potentials, Visual - drug effects Female Humans Liothyronine Low contrast letter acuity Male Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Neurology Outcome Assessment, Health Care - standards Phase I Remyelination Remyelination - drug effects Reproducibility of Results Triiodothyronine - administration & dosage Triiodothyronine - adverse effects Triiodothyronine - pharmacology Visual Visual Acuity - drug effects
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!